ChiCTR2400083854 版本V1.0 版本创建时间2024/05/06 14:26:00 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400083854 

最近更新日期:

Date of Last Refreshed on:

2024-05-06 14:25:54 

注册时间:

Date of Registration:

2024-05-06 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

智能手环监测下有氧运动辅助治疗抑郁症的个体化探究:随机对照试验

Public title:

Individualized exploration of aerobic exercise-assisted treatment of depression monitored by smart band: a randomized controlled trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

智能手环监测下有氧运动辅助治疗抑郁症的个体化探究:随机对照试验

Scientific title:

Individualized exploration of aerobic exercise-assisted treatment of depression monitored by smart band: a randomized controlled trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

赵国瑞 

研究负责人:

岳伟华 

Applicant:

Guorui Zhao 

Study leader:

Weihua Yue 

申请注册联系人电话:

Applicant telephone:

+86 158 3941 5123

研究负责人电话:

Study leader's telephone:

+86 136 6135 2950

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

grzhao@bjmu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

dryue@bjmu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市海淀区花园北路51号

研究负责人通讯地址:

北京市海淀区花园北路51号

Applicant address:

No. 51 Hua Yuan Bei Road, Haidian District, Beijing 100191, P. R. CHINA

Study leader's address:

No. 51 Hua Yuan Bei Road, Haidian District, Beijing 100191, P. R. CHINA

申请注册联系人邮政编码:

Applicant postcode:

100191

研究负责人邮政编码:

Study leader's postcode:

100191

申请人所在单位:

北京大学第六医院

Applicant's institution:

Peking University Sixth Hospital

研究负责人所在单位:

北京大学第六医院

Affiliation of the Leader:

Peking University Sixth Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

(2024)伦审第(11)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

北京大学第六医院伦理委员会

Name of the ethic committee:

Ethics Committee of Peking University Sixth Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024-02-29 00:00:00

伦理委员会联系人:

王雪芹

Contact Name of the ethic committee:

Wang Xueqin

伦理委员会联系地址:

北京市海淀区花园北路51号

Contact Address of the ethic committee:

No. 51 Hua Yuan Bei Road, Haidian District, Beijing 100191, P. R. CHINA

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 6272 3769

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

北京大学第六医院

Primary sponsor:

Peking University Sixth Hospital

研究实施负责(组长)单位地址:

北京市海淀区花园北路51号

Primary sponsor's address:

No. 51 Hua Yuan Bei Road, Haidian District, Beijing 100191, P. R. CHINA

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

海淀区

Country:

China

Province:

Beijing

City:

Haidian

单位(医院):

北京大学第六医院

具体地址:

北京市海淀区花园北路51号

Institution
hospital:

Peking University Sixth Hospital

Address:

No. 51 Hua Yuan Bei Road, Haidian District, Beijing 100191, P. R. CHINA

经费或物资来源:

研究者自筹

Source(s) of funding:

Self-funded

Target disease:

major depressive disorder

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

量化基于智能穿戴设备监测下的有氧运动对辅助治疗抑郁症和和改善认知功能的相对效果,利用影像遗传等手段探寻有氧运动发挥作用的机制,并确定运动适宜人群,为精准化运动处方提供依据。  

Objectives of Study:

To quantify the relative effectiveness of aerobic exercise based on smart wearable devices monitoring in assisting in the treatment of depression and and improving cognitive function. To explore the mechanisms by which aerobic exercise works and to identify the appropriate population for exercise, providing a basis for precision exercise prescription.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 年龄18-60岁(包括18和60岁),性别不限,汉族; 2. 通过简明国际神经精神访谈(Mini-International Neuropsychiatric Interview, MINI),符合《精神障碍诊断与统计手册(第5版)》(Diagnostic and Statistical Manual of Mental Disorders–fifth edition,DSM-5)抑郁障碍的诊断标准; 3. 门诊或住院患者;汉密尔顿抑郁量表17项(HAMD17)≥14分; 心境障碍问卷 (MDQ) 筛查阴性以排除双相障碍患者;且临床总体印象严重程度 (Clinical Global Impressions-Severity, CGI-S) 评分≥ 4分; 4. 维持抗抑郁药单药(SSRI类)治疗,剂量为:氟西汀当量20-40mg/d。在失眠和焦虑发作时可以合并使用劳拉0.5mg/次,思诺思5-10mg/n; 5. 获得患者的书面知情同意。

Inclusion criteria

1. aged 18-60 years (including 18 and 60 years), gender-neutral, Han Chinese; 2. meet the Diagnostic and Statistical Manual of Mental Disorders-fifth edition (DSM-5) diagnostic criteria for depressive disorders through the Mini-International Neuropsychiatric Interview (MINI). 3. outpatient or inpatient; Hamilton Depression Scale 17 (HAMD17) ≥ 14; negative Mood Disorder Questionnaire (MDQ) screen to exclude patients with bipolar disorder; and Clinical Global Impressions-Severity (CGI-S) score ≥ 4; 4. maintenance antidepressant monotherapy (SSRI class) at a dose of: fluoxetine equivalents 20-40 mg/d. Laura 0.5 mg/dose and Snus 5-10 mg/n may be combined in insomnia and anxiety episodes; 5. written informed consent was obtained from the patient.

排除标准:

1. 符合其他精神障碍诊断者,包括精神分裂症、双相障碍、酒精或药物滥用/依赖、进食障碍等; 2. 智力障碍者及其他原因无法配合者,或在发病期无民事行为能力或民事行为能力不完整者; 3. 患有神经系统疾病和脑器质性疾病(如脑卒中、脑出血、脑肿瘤、帕金森病、癫痫等)及严重脑外伤史; 4. 患有高血压、心脏病等运动风险较高的疾病; 5. 正在接受系统心理治疗者; 6. 心肺健康3分钟台阶测试男性恢复心率>131,女性恢复心率>140; 7. 躯体受限无法参加体育锻炼者; 8. 体力活动准备问卷(PAR-Q)≥2分者; 9. 处于妊娠期,或有磁共振成像检查禁忌症者; 10. 严重自杀倾向者或有伤人风险者;

Exclusion criteria:

1. persons who meet the diagnosis of other mental disorders, including schizophrenia, bipolar disorder, alcohol or drug abuse/dependence, etc; 2. persons who are intellectual disabled and otherwise unable to cooperate, or who are incapacitated or have incomplete civil capacity during the period of onset of the disease 3. those suffering from neurological disorders and organic brain diseases (e.g. stroke, brain hemorrhage, brain tumor, Parkinson's disease, epilepsy, etc.) and history of severe traumatic brain injury 4. suffering from diseases with high risk of exercise such as high blood pressure and heart disease 5. those who are undergoing systematic psychological treatment; 6. cardiorespiratory fitness 3-minute step test with recovery heart rate >131 for males and >140 for females; 7. persons with physical limitations that prevent them from participating in physical activity; 8. who have a Physical Activity Readiness Questionnaire (PAR-Q) score of ≥2; 9. those who are pregnant or have contraindications to magnetic resonance imaging (MRI) examination 10. those who are severely suicidal or at risk of injury;

研究实施时间:

Study execute time:

From 2024-03-31 00:00:00 To 2025-05-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-05-06 00:00:00 To 2025-05-10 00:00:00  

干预措施:

Interventions:

组别:

有氧运动组

样本量:

40

Group:

Aerobic exercise group

Sample size:

干预措施:

参照美国运动医学学会编制的《ACSM运动测试与运动处方指南(第十版)》的制定运动处方,运动处方遵循FITT-VP基本原则,即频率(frequency)、强度(intensity)、方式(type)、时间(time)、总量(volume)、运动进阶(progression)。运动治疗为期8周,每周3天,每次50分钟,其中包括5分钟热身、40分钟运动、5分钟伸展;运动强度使用目前研究支持的中等强度,即:有氧运动达60%~75%最大心率(HRmax),最大心率使用220-年龄进行估算,运动前1周进行逐步运动进阶(如:由每次30分钟到50分钟),第2周达到推荐运动强度。运动干预开始前,向患者说明运动的注意事项:受试者可用慢跑和快走的方式相结合,并由运动医学背景主任医师评估运动安全性,并给予推荐的运动方式进行参考,无论何种方式都要达到指定的运动强度。要求被试在每次运动前的1小时内不可摄入咖啡因、 尼古丁等物质,防止对心率造成影响。提醒被试在运动前1小时不可进食,运动期间准备好饮用水,及时补充水分等等。运动情况由研究人员通过手环和app后台进行监督,同时与受试者之间保持良好的沟通和交流,及时了解受试者的需求与反馈,解答疑问以确保受试者在运动干预过程中的有效性和安全性。

干预措施代码:

Intervention:

The exercise prescription was formulated according to the ACSM Exercise Testing and Exercise Prescription Guidelines (10th Edition) prepared by the American College of Sports Medicine. The exercise prescription followed the basic principles of FITT-VP. Namely, frequency, intensity, type, time, volume, and progression. The exercise therapy lasted for 8 weeks, 3 days a week, 50 minutes each time, which included 5 minutes of warm-up, 40 minutes of exercise, and 5 minutes of stretching. The exercise intensity was moderate, that is, 60%-75% of the maximum heart rate (HRmax) of aerobic exercise, and the maximum heart rate was estimated by 220-age. One week before exercise, the exercise was gradually increased (e.g., from 30 minutes to 50 minutes per session), and the recommended exercise intensity was reached in the second week. Before the start of the exercise intervention, the patients were explained the precautions for exercise: the subjects could combine jogging and brisk walking, and the safety of exercise was evaluated by a chief physician with a sports medicine background, and the recommended exercise mode was given as a reference, regardless of which mode was to achieve the specified exercise intensity. The subjects were asked not to take caffeine, nicotine and other substances within 1 hour before each exercise to prevent the effect on heart rate. The subjects were reminded not to eat 1 hour before exercise, to prepare drinking water during exercise, to replenish water in time, and so on. The exercise was monitored by the researchers through the bracelet and app background. At the same time, the researchers maintained good communication with the subjects, understood the needs and feedback of the subjects in time, and answered questions to ensure the effectiveness and safety of the subjects in the process of exercise intervention.

Intervention code:

组别:

等待对照组

样本量:

40

Group:

Waiting control group

Sample size:

干预措施:

等待对照组在8周随访观察结束后获得运动处方建议,并进行相应运动训练。

干预措施代码:

Intervention:

The control group received advice on exercise prescription and exercise training after 8 weeks of follow-up observation.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

海淀区 

Country:

China 

Province:

Beijing 

City:

Haidian 

单位(医院):

北京大学第六医院 

单位级别:

三甲 

Institution
hospital:

Peking University Sixth Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

汉密尔顿抑郁量表

指标类型:

主要指标

Outcome:

HAMD Hamilton Depression Rating Scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

蒙哥马利抑郁评定量表

指标类型:

次要指标

Outcome:

Montgomery-?sberg Depression Rating Scale (MADRS)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Thinc-Integrated 工具包 (THINC-it)

指标类型:

次要指标

Outcome:

Thinc-Integrated Tool (THINC-it)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 60 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由不参与本研究的研究者进行简单随机,将随机数字随机划分为A、B两组,A组使用有氧运动,B组为等待对照组。

Randomization Procedure (please state who generates the random number sequence and by what method):

Simple randomization was performed by an investigator not involved in this study, and random numbers were randomly assigned to groups A and B. Group A was given aerobic exercise, and group B was a waiting control group.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

研究过程中严格遵循单盲原则。进行量表评估的研究员对干预分组不知情;随机数字由不参与本研究的研究者生成。

Blinding:

The single-blind principle was strictly followed during the study. The researchers who performed the scale assessments were unaware of the intervention group assignments. The random numbers were generated by investigators not involved in this study.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不适用

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Not applicable

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表(Case Record Form, CRF)+电子采集和管理系统(Electronic Data Capture, EDC)

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF+EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-05-06 14:25:54